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958Toll-Like 4 Receptor Variant, Asp299Gly, and Reduced
Risk of Hemorrhagic Cystitis after Hematopoietic
Stem Cell Transplantation
Bernd Gruhn,1, Norman Kl€oppner,1 Nadine Pfaffendorf-Regler,1 James Beck,1 Felix Zintl,1
Stephan Bartholom€a,2 Klaus-Michael Debatin,2 Daniel Steinbach2Hemorrhagic cystitis (HC) is a major cause of morbidity after hematopoietic stem cell transplantation.
Toll-like receptor 4 (TLR4) is a pattern recognition receptor of the innate immune system and induces
inflammation. Individuals with the single nucleotide polymorphisms Thr399Ile (rs4986791) or Asp299Gly
(rs4986790) of TLR4 show diminished inflammatory responsiveness to endotoxins. The genotype of
TLR4 was determined in 166 children who underwent allogeneic hematopoietic stem cell transplantation
and in their donors. Asp299Gly was present in 21 patients (13%) and 24 donors (14%). Thr399Ile was found
in 22 patients (13%) and 25 donors (15%). The incidence of HC was significantly lower in patients with
Asp299Gly (0% vs 23%; P5.009) and in patients who underwent transplantation from a donor with Asp299-
Gly (4% vs 23%; P 5 .05). The trend was the same for Thr399Ile—donor positive (8% vs 22%; P 5 .17),
recipient positive (9% vs 22%; P5 .25), donor or recipient positive (8% vs 23%; P5 .04). Multivariate analysis
revealed age, conditioning with busulfan, and absence of Asp299Gly as independent risk factors for HC. In
conclusion, the TLR4 Asp299Gly variant seems to confer protection against hemorrhagic cystitis. This study
provides the first indication that the innate immune system through TLR4 signaling pathway plays a role in the
pathogenesis of HC after hematopoietic stem cell transplantation.
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Hemorrhagic cystitis is a frequent and important
cause of morbidity after hematopoietic stem cell trans-
plantation.Thepathogenesis is not fully understood.Ge-
netic risk factors have not been identified. BK virus or
adenovirus is found in the urine of most patients with
hemorrhagic cystitis, but not all patients with either of
these viruses in the urine develop this complication [1-3].
Toll-like receptors (TLRs) are pattern-recogni-
tion receptors of the innate immune system and im-
portant for inflammatory response [4]. The main1Department of Pediatrics, University Hospital of Jena,
Germany; and 2Department of Pediatrics, UlmUniversity,
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(LPS) of gram-negative bacteria. The signal transduc-
tion pathway of TLR4 is partially known: LPS is
opsonized by LPS-binding protein and subsequently
recognized by CD14. The binding protein-CD14
complex then activates TLR4, which signals through
IL-1R-associated kinase. This results in activation
of nuclear factor kB and mitogen-activated protein
kinases and triggers cytokine production [4-6].
Two functionally relevant single-nucleotide poly-
morphisms (SNP) of TLR4, Asp299Gly (rs4986790)
and Thr399Ile (rs4986791), have been described
[5,7-9]. Airway responsiveness to inhaled LPS is
significantly lower in individuals heterozygous or
homozygous for the Asp299Gly or Thr399Ile alleles
than in those with the common genotype [9]. The
Asp299Gly variant is associated with a reduced risk
of recurrent urinary tract infection in adult women
[10]. C3H/HeJ mice that lack functional TLR4 recep-
tors do not develop cystitis after intravesical instilla-
tion of Escherichia coli [11].
The latter 2 findings prompted our hypothesis that
TLR4 could also play a role in the development of
hemorrhagic cystitis and that the risk of this complica-
tion could be associatedwith polymorphisms ofTLR4.
Biol Blood Marrow Transplant 18:958-973, 2012 959Hemorrhagic Cystitis and Polymorphisms of TLR4TLR4 is expressed in the epithelium of the urinary
tract [12] as well as in granulocytes and monocytes
[13,14]. Therefore, the genotype of the donor as well
as the genotype of the receptor could be relevant for
this complication.DESIGN AND METHODS
Patients
The study population consisted of 166 children or
adolescents and their respective donorswhounderwent
stem cell transplantation at the University Children’s
Hospital Jena between 1990 and 2007.
The criteria for enrollment in this study were avail-
ability of cryopreserved blood or bone marrow cells
and the informed consent from the donors and the
patients and/or their parents. Clinical characteristics
of the patients are described in Table 1.
The vast majority of patients underwent transplan-
tation because of hematologic malignancies (Table 1).
The category ‘‘Other Diseases’’ in Table 1 included 6
patientswith storage disease, 2with inborn immunode-
ficiency, 2 with osteopetrosis, 1 with malignant histio-
cytosis, 1 with congenital amegacaryocytosis, and 1
who had Diamond Blackfan anemia.
Allogeneic bone marrow (n 5 107) or peripheral
blood stem cells (n5 59) were used for transplantation.
The donor was HLA-matched unrelated in 47% (n 5
77) of transplantations and HLA-identical related in
33% (n 5 55) of transplantations. In 12 (7%) patients,
the donor was haploidentical related, and 22 (13%)
patients underwent transplantation from HLA-
mismatched donors. Conditioning regimen was mye-
loablative in all cases. Busulfan-containing regimens
were administered in 78 patients. Total-body irradia-
tion was used in 77 patients. The other patients were
conditioned with high-dose cyclophosphamide (n 5
7) or thiotepa (n 5 4).
The level of hemorrhagic cystitis was defined as
moderate (macroscopic hematuria), severe (hematuria
with formation of intravesical clots), or very severe
(urinary obstruction with renal impairment).
During the first 8 weeks after transplantation, each
patient’s urine was analyzed for hematuria and for ad-
enovirus and BK-virus (PCR) at least once per week.
Acute and chronic graft-versus host disease was
diagnosed and graded according to standard criteria
[15,16].
SNPAnalysis
Sample collection and processingwas performed as
described [17,18]. Briefly, samples were obtained from
blood or bone marrow aspirates. Mononuclear cells
were purified by Ficoll-Hypaque (Sigma, St. Louis,
MO, USA) density gradients (density . 1.077 g/mL)
and cryopreserved in liquid nitrogen. Genomic DNAwas isolated using theHigh Pure PCRTemplate Prep-
aration Kit (Roche, Mannheim, Germany) according
to the manufacturer’s instructions. The genotype was
determined using ready-to-use TaqMan SNPGeno-
typing Assays and the ABI PrismTM 7700 Sequence
Detector (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions.
The assay IDs were C_11722237_20 for the Thr399Ile
variant (rs4986791) and C_11722238_20 for the
Asp299Gly variant (rs4986790). Details about these
assays are available at www.appliedbiosystems.com.Statistics
The P values for the association between hemor-
rhagic cystitis and genotype were calculated by Fisher
exact test. Individual risk factors for hemorrhagic cysti-
tis were analyzed by binary logistic regression analysis.
Multivariable analysis of risk factors for hemorrhagic
cystitis was calculated by forward stepwise multivari-
able binary logistic regression analysis. All calculations
were done using the SPSS 11.0 program (SPSS, Inc.,
Chicago, IL, USA).RESULTS
Frequency of TLR4 Polymorphisms
The number of analyzed donor/patient pairs was
166. The frequency of the polymorphisms in patients
and donors were similar to previously published data
[5,10]. The Asp299Gly variant was found in 21
(13%; 95% confidence interval [CI], 8%-18%)
patients and in 24 (14%; 95% CI, 10%-20%)
donors. None of the individuals was homozygous for
this SNP. In 10 (6%; 95% CI, 3%-11%) cases, the
polymorphism was found in donor and patient.
The Thr399Ile variant was found in 22 (13%; 95%
CI, 9%-19%) patients and in 25 (15%; 95% CI, 10%-
21%) donors.None of the individuals was homozygous
for this SNP. In 10 (6%; 95% CI, 3%-11%) cases, the
polymorphism was found in donor and patient.
In accordance with previous studies [8,10], we
found a strong linkage between Asp299Gly and
Thr399Ile. Only 1 patient and no donor were positive
for Asp299Gly but negative for Thr399Ile. Two
patients and 1 donor were positive for Thr399Ile but
negative for Asp299Gly.Frequency of Hemorrhagic Cystitis
Hemorrhagic cystitis occurred in 33 (19%; 95%
CI, 15%-27%) patients. A moderate course of the dis-
ease with hematuria alone was seen in 9 of these
patients. Severe hemorrhagic cystitis with formation
of intravesical clots but normal renal function occurred
in 13 children, whereas 10 children suffered from very
Table 1. Characteristics of Patients and Donors
All Patients
SNP Asp299Gly
P Value
Donor or Recipient Positive Donor and Recipient wt
Number Percent Number Percent Number Percent
166 100 35 100 131 100
Patient characteristics
Sex
Male 103 62.0 25 71 78 60 .24
Female 63 38.0 10 29 53 40
Median age (range) 12 (3-19) 10 (0-26) .11
Underlying disease
AML 72 43.4 7 20 31 24 .11
ALL/NHL 38 22.9 13 37 59 45
MDS 21 12.7 5 14 16 12
CML 12 7.2 1 3 11 8
SAA 10 6.0 2 6 8 6
Other 13 7.8 6 17 7 5
TBI
Yes 77 46.4 15 43 62 47 .71
No 89 53.6 20 57 69 53
Busulfan
Yes 78 47.0 19 54 59 45 .35
No 88 53.0 16 46 72 55
GVHD prophylaxis
MTX + CSA 107 64.5 19 54 88 67 .32
CSA 41 24.7 11 31 30 23
No prophylaxis 18 10.8 5 14 13 10
Acute GVHD
Yes 77 46.4 16 46 61 47 .99
No 89 53.6 19 54 70 53
Chronic GVHD
Yes 31 18.7 5 14 26 20 .63
No 135 81.3 30 86 105 80
Donor characteristics
Sex
Male 105 63.3 23 66 82 63 .84
Female 61 36.7 12 34 49 37
Tissue compatibility
MFD 55 33.1 13 37 42 32 .04
MUD 77 46.4 10 29 67 51
MMD 22 13.3 7 20 15 11
Haploidentical 12 7.2 5 14 7 5
Cell type
Bone marrow 107 64.5 23 66 84 64 .98
Peripheral stem cells 59 35.5 12 34 47 36
MTX indicates methotrexate; GVHD, graft-versus-host disease; CSA, cyclosporine A; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; SAA, severe aplastic anemia; MFD, matched family
donor; MUD, matched unrelated donor; MMD, mismatched donor; TBI, total-body irradiation.
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and renal impairment.
In themajority of these complications (n5 27; 82%;
95%CI, 66%-91%), the urinewas positive for BK-virus
PCR. In 1 patient, the urine was positive for adenovirus.
No virus was found in the urine of 5 patients with
hemorrhagic cystitis. In most virus-positive cases, virus
was found before the onset of hemorrhagic cystitis (n5
22; 81%; 95% CI, 63%-92%).Hemorrhagic Cystitis and TLR4-Polymorphism
TheAsp299Glyvariantwasassociatedwitha signif-
icantly lower incidence of hemorrhagic cystitis. Inter-
estingly, this association was statistically significantfor the genotype of the donor aswell as for the genotype
of the recipient (Table 2). The same trend was found
for the Thr399Ile variant, but statistical significance
was only achieved in the combined analysis of donor
and recipient genotype (Table 2).
Donor and recipient were positive for Asp299Gly
in 10 cases. None of these patients developed a hem-
orrhagic cystitis. In 10 cases, donor and recipient
were positive for Thr399Ile. Only 1 of these patients
developed a hemorrhagic cystitis.
Because of the strong linkage between the 2 poly-
morphisms,we couldnot determinewhether bothpoly-
morphisms are independently associated with a lower
incidence of hemorrhagic cystitis. The only 2 patients
who were positive for Thr399Ile and negative for
Table 2. Hemorrhagic Cystitis and TLR4-Polymorphisms
Hemorrhagic Cystitis
Fisher Exact Test
P ValueYes No
Asp299Gly
Donor
Yes 1 (4%) 23 (96%) .05
No (wt) 32 (23%) 110 (77%)
Recipient .009
Yes 0 (0%) 21 (100%)
No (wt) 33 (23%) 112 (77%)
Donor or recipient
Yes 1 (3%) 34 (97%) .003
No (wt) 32 (24%) 99 (76%)
Thr399lle
Donor
Yes 2 (8%) 23 (92%) .17
No (wt) 31 (22%) 110 (78%)
Recipient
Yes 2 (9%) 20 (91%) .25
No (wt) 31 (22%) 113 (78%)
Donor or recipient
Yes 3 (8%) 35 (92%) .04
No (wt) 30 (23%) 98 (77%)
Table 3. Binary Logistic Regression for Risk Factors of
Hemorrhagic Cystitis
Patient Characteristic
Hazard Ratio for Risk of Hemorrhagic
Cystitis
Hazard Ratio
95% Confidence
Interval P Value
Sex 0.92 0.42-2.1 .85
Age 1.1a 1.03-1.19 .004
Acute GVHD 2 0.91-4.3 .083
Chronic GVHD 1.7 0.68-4.4 .25
Conditioning with busulfan 2.8 1.2-6.1 .013
Conditioning with TBI 0.42 0.12-0.97 .043
Thr399lle in donor or
recipient
0.28 0.08-0.98 .046
Asp299Gly in donor or
recipient
0.091 0.012-0.69 .021
GVHD indicates graft-versus-host disease; TBI, total-body irridiation.
aHazard ratio per each additional year.
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only patient who was positive for Asp299Gly and nega-
tive for Thr399Ile did not have this complication.
Therefore, it is possible that only theAsp299Gly variant
is relevant for the reduced risk of hemorrhagic cystitis.
Other Risk Factors for Hemorrhagic Cystitis
The risk of hemorrhagic cystitis was significantly
higher in older patients and in patients who received
a conditioning regimen including busulfan (Table 3).
We did not observe a significant association between
donor type and hemorrhagic cystitis. This complica-
tion occurred in 21% (16/77) of the patients with
a matched unrelated donor, 16% (9 of 55) of the pa-
tients with a matched family donor, 17% (2 of 12) of
those with a haploidentical donor, and 27% (6 of 22)
with a mismatched donor (P 5 .73).
All variables that are displayed in Table 3 were
also analyzed in amultivariable stepwise binary logistic
regression analysis. Age, conditioning with busulfan,
and Asp299Gly in donor and/or recipient were identi-
fied as independent risk factors for hemorrhagic cysti-
tis. In the model that included all 3 variables, the
hazard ratios were 1.1 per year (P 5 .008) for age, 4.2
(P 5 .001) for conditioning with busulfan, and 0.07
(P 5 .014) for Asp299Gly in donor and/or recipient.DISCUSSION
Toourknowledge, this is thefirst reportonagenetic
risk factor for hemorrhagic cystitis after stem cell trans-
plantation. These findings can help to achieve a better
understanding of this troublesome complication.
TLR4polymorphism in both recipient anddonor is
associatedwith a reduced risk of hemorrhagic cystitis. Apossible explanation for this finding is the expression of
TLR4 in the epithelium of the urinary tract [12] as well
as in granulocytes andmonocytes [13,14]. The function
of TLR4 in epithelial cells depends on the recipient,
whereas the function in the blood cells is determined
by the donor genotype.
The mere statistical correlation of a genetic poly-
morphism with a clinical complication does not prove
a functional link between the two. In the case of TLR4
and hemorrhagic cystitis, there are additional data
available showing that the genetic polymorphism in-
deed has an impact on the function of the correspond-
ing protein and that the protein has the potential to
influence this clinical complication.
TLR4 is a pattern recognition receptor that plays
an important role in the innate immune system. As de-
scribed previously, it induces inflammation after acti-
vation by gram-negative bacteria. This mechanism
does not depend on an intact specific immune system,
and it can take place in the early stages after stem cell
transplantation. The finding that TLR4-deficient
mice do not develop cystitis after intravesical instilla-
tion of Escherichia coli [11] strongly suggests that
TLR4 plays a relevant role in inflammatory responses
of the urinary tract.
A functional impact of the polymorphisms
Asp299Gly and Thr399Ile in vitro was shown by
Rallabhandi et al. [19], who found a reduced response
to LPS in cells expressing these variants. There is also
a growing body of evidence to indicate that these
polymorphisms are relevant in vivo. Hawn et al. [10]
showed that the Asp299Gly variant was associated
with a reduced risk of recurrent urinary tract infections
in adult women but not with a reduced risk of pyelone-
phritis. Karoly et al. [20] found an increased risk of uri-
nary tract infections in children with the Asp299Gly
variant. A possible explanation is that the stronger
inflammatory response to bacteriuria in individuals
with the wild-type TLR4 helps to prevent serious
962 Biol Blood Marrow Transplant 18:958-973, 2012B. Gruhn et al.infections, but on the other hand, can cause inflamma-
tory symptoms in transient or self-limiting bacteriuria.
This hypothesis would also be in line with data from
Ragnarsdottir et al. [13], who showed reduced levels
of TLR4 expression in granulocytes from patients
with asymptomatic bacteriuria.
In addition to urinary tract infections, TLR4 and
its polymorphisms were also linked to a number of
other infectious and inflammatory diseases [7].
A limitation of our study is the strong heterogene-
ity of the study population (Table 1). Therefore,
we checked for differences in the main characteristics
between transplantations with wild-type versus
Asp299Gly-positive individuals. The only significant
difference was a higher proportion of patients with
a mismatched or haploidentical donor in the group
with Asp299Gly (Table 1). This finding does not ham-
per our conclusions because the overall frequency of
hemorrhagic cystitis was even higher in patients with
mismatched or haploidentical donors.
Table 1 combines transplantations with Asp299-
Gly in the donor and/or recipient. When the same
analysis was performed separately for positive donors
and for positive recipients, none of the patient or do-
nor characteristics showed statistically significant dif-
ferences to the wild-type group. Because of the
strong linkage between the 2 polymorphisms of
TLR4, the data presented for Asp299Gly in Table 1
are almost identical for Thr399Ile.
In conclusion, we hypothesize that TLR4 plays an
important role in the induction of inflammation in
hemorrhagic cystitis. A reduced function of TLR4 be-
cause of the polymorphism Asp299Gly and/or
Thr399Ile significantly reduces the risk of this compli-
cation of stem cell transplantation.
It was very recently shown that ciprofloxacin pro-
phylaxis can efficiently reduce the risk of hemorrhagic
cystitis [21]. The authors suggested that the mecha-
nism of action is a direct inhibition of BK viral replica-
tion. Our results indicate that a reduction of bacterial
contamination, and hence, a reduced activation of
TLR4 might be another mechanism of action.
Many patients with the BK virus in the urine do not
develop hemorrhagic cystitis [22]. We hypothesize
that the damage caused by the BK virus sensitizes the
urinary epithelia and renders it susceptible for hemor-
rhagic cystitis. A second hit, caused by bacteria and
mediated via TLR4, could be necessary to induce the
full picture of hemorrhagic cystitis.
This hypothesis should be tested in further clinical
and laboratory studies.ACKNOWLEDGMENTS
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Pediatric Acute Lymphoblastic Leukemia: Effect of
Minimal Residual Disease on Relapse and Survival
Veronika Bachanova,1 Michael J. Burke,2 Sophia Yohe,3 Qing Cao,4 Karamjeet Sandhu,5
Timothy P. Singleton,3 Claudio G. Brunstein,1 John E. Wagner,1 Michael R. Verneris,1
Daniel J. Weisdorf1Data on pretransplantation minimal residual disease (MRD) and outcomes of umbilical cord blood transplan-
tation (UCBT) are limited. Out of the 143 patients with acute lymphoblastic leukemia (ALL) who underwent
UCBTat the University of Minnesota between 2004 and 2010, we evaluated 86 patients with available MRD
assessment data by 4- and 8-color flow cytometry analysis immediately before transplantation. Ten patients
(11.6%) were MRD-positive, and 76 were MRD-negative (88.4%). Most of the patients (82%) received mye-
loablative conditioning. GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. In multi-
variate analysis, age, disease status (complete remission [CR] 1 versus CR2/CR3), disease group
(precursor B cell ALL versus Philadelphia chromosome–positive ALL versus T cell ALL), and time to trans-
plantation had no impact on relapse. Patients with MRD before UCBT had a greater incidence of relapse at 2
years (relapse rate, 30%; 95% confidence interval [CI], 4%-56%) and lower 3-year disease-free survival (30%;
95% CI, 7%-58%) compared with those without MRD (relapse rate, 16%; 95% CI, 8%-25%; P5 .05; disease-
free survival, 55%; 95% CI, 43%-66%; P5 .02). Our data suggest that in patients with ALL, achieving an MRD-
negative state before UCBT improves outcomes.
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Relapse and transplantation-related mortality
(TRM) continue to be the greatest hurdles facing pa-
tients who undergo allogeneic hematopoietic cell
transplantation (allo-HCT) for acute lymphoblastic
leukemia (ALL) [1-4]. Identifying the patients at
greatest risk for post-HCT failure is critical to the
application of risk-adapted therapy. Recent pediatric
ALL studies suggest that minimal residual disease
(MRD) detected immediately before allo-HCT is an
independent predictor of the risk of relapse [5-9];
however, data on pretransplantation MRD in adults
undergoing allo-HCT for ALL are limited and in-
consistent [10-14]. In the prospective UKALL XII/
ECOG2993 trial, the presence of MRD evaluated
